Fennec Pharmaceuticals (id:5476 FENC)
5.32 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 10:26:03 AM)
Exchange closed, opens in 1 day 23 hours
13.68 USD (13.68%)
32.01 USD (32.01%)
17.18 USD (17.18%)
-21.07 USD (-21.07%)
-39.55 USD (-39.55%)
-7.48 USD (-7.48%)
-57.61 USD (-57.61%)
About Fennec Pharmaceuticals
Market Capitalization 110.22M
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
| Headquarters (address) |
68 TW Alexander Drive Research Triangle Park 27709 NC United States |
| Phone | 919 636 4530 |
| Website | https://www.fennecpharma.com |
| Employees | 29 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | FENC |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 3.96 - 11.92 |
| Market Capitalization | 110.22M |
| P/E trailing | 60.43 |
| P/E forward | 10.78 |
| Price/Sale | 2.23 |
| Price/Book | -28.16 |
| Beta | 0.267 |
| EPS | -0.040 |
| EPS United States (ID:6, base:3400) | 24.26 |